| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | EGP1; GP50; M1S1; EGP-1; TROP2; GA7331; GA733-1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human TACSTD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TACSTD2(TROP2)抗体的3篇代表性文献摘要，按实际研究领域分类整理：
---
1. **文献名称**：*TROP2: A Novel Therapeutic Target in Solid Tumors*
**作者**：Cubas R, Li M, Chen C, Yao Q
**摘要**：
综述了TROP2在多种实体瘤(如乳腺癌、胰腺癌)中的过表达及其促癌机制，重点讨论了抗TROP2单克隆抗体(如Sacituzumab)在靶向治疗中的应用，包括抗体偶联药物(ADC)的临床前和临床试验数据。
2. **文献名称**：*Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer*
**作者**：Bardia A, et al.
**摘要**：
报告了抗TROP2抗体药物偶联物Sacituzumab的III期临床试验结果，证实其在难治性三阴性乳腺癌中显著提升客观缓解率(ORR)和无进展生存期(PFS)，验证了TROP2抗体作为载体的靶向递送有效性。
3. **文献名称**：*TROP2 Expression in Prostate Cancer Stem Cells*
**作者**：Muhlmann G, et al.
**摘要**：
通过抗TROP2抗体的流式细胞分选技术，鉴定出前列腺癌干细胞亚群，揭示TROP2高表达与肿瘤干性、转移潜能的相关性，为抗体介导的靶向清除策略提供依据。
---
**备注**：TACSTD2(TROP2)抗体研究主要集中于肿瘤靶向治疗(尤其是ADC药物开发)和癌症干细胞研究领域。如需具体文献DOI或发表年份，可进一步补充关键词缩小范围。
The TACSTD2 antibody targets Tumor-Associated Calcium Signal Transducer 2 (TACSTD2), also known as Trop-2 or EpCAM2. a transmembrane glycoprotein encoded by the *TACSTD2* gene. Initially identified as a tumor-associated antigen, TACSTD2 is overexpressed in various epithelial cancers, including pancreatic, colorectal, and breast cancers, while exhibiting limited expression in normal tissues. Its structure includes an extracellular domain with epidermal growth factor (EGF)-like repeats, a transmembrane region, and a short cytoplasmic tail. TACSTD2 regulates cell-cell adhesion, intracellular calcium signaling, and promotes tumor growth, metastasis, and stemness by activating pathways like MAPK/ERK and PI3K/AKT.
Antibodies against TACSTD2 have gained attention as diagnostic and therapeutic tools. Diagnostic applications include immunohistochemical detection of TACSTD2 in tumor biopsies to assess malignancy and prognosis. Therapeutically, anti-TACSTD2 antibodies are engineered as antibody-drug conjugates (ADCs) or bispecific antibodies. Sacituzumab govitecan, an ADC targeting TACSTD2. is FDA-approved for metastatic triple-negative breast cancer and urothelial carcinoma, demonstrating clinical efficacy. Research also explores bispecific formats to enhance immune cell targeting.
Despite promise, challenges like on-target off-tumor toxicity and resistance mechanisms require further study. TACSTD2 antibodies represent a bridge between tumor biology and precision oncology, with ongoing trials expanding their potential in solid tumors.
×
